Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence SEAEDASLLSFMQGYMKHATK
Primary information
sequence IDSeq_6960
Peptide sequenceSEAEDASLLSFMQGYMKHATK
CancerPDF_ID CancerPDF_ID1748, CancerPDF_ID2986, CancerPDF_ID3738,
PMID21136997,21136997,27026199
Protein NameApolipoprotein C-III precursor (Apo-CIII),Apolipoprotein C-III,Apolipoprotein C-III
UniprotKB Entry NameAPOC3_HUMAN,APOC3_HUMAN,APOC3_HUMAN
FluidSerum,Plasma,Urine
M/Z2343.08752,2343.0875,NA
Charge1,1,NA
Mass (in Da)NA,NA,NA
fdrNA,NA,2343.1
Profiling TechniqueLC-MS,LC-MS,"CE-MS, Micro-TOF-MS"
Peptide Identification techniqueLC-MS-MS/MS,LC-MS-MS/MS,MS-MS
Quantification TechniqueLC-ESI-MS,LC-ESI-MS,NA
Labelled/Label FreeLabel Free,Label Free,Label Free
FDRNA,NA,NA
CancerPDF_ID CancerPDF_ID1748, CancerPDF_ID2986, CancerPDF_ID3738,
p-ValueNA,NA,less than 0.05
SoftwareMASCOT(v. 2.2.01),MASCOT(v. 2.2.01),Proteome Discoverer 1.2
Length21,21,21
Cancer TypeColorectal cancer,Normal,Bladder cancer
DatabaseSwissProt Database,SwissProt Database,Uniprot Human non-redundant Database
ModificationNA,NA,NA
Number of Patients30 patients and 30 healthy controls,27 healthy individuals, 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls)
RegulationNA,NA,Differentially expressed between recurrence of UBC vs recurrence control
ValidationLeave One out Cross validation,Leave One out Cross validation,Independent Validation
SensitivityNA,NA,For testing dataset 88%
SpecificityNA,NA,For testing dataset 51%
AccuracyNA,NA,NA
Peptide AtlasPeptideAtlas
IEDB